GW Pharmaceuticals PLC Presenting at BAML 2014 Health Care Conference
09 May 2014 - 2:00AM
RNS Non-Regulatory
TIDMGWP
GW Pharmaceuticals PLC
08 May 2014
GW Pharmaceuticals to Present at the Bank of America Merrill
Lynch 2014 Health Care Conference
London, UK, 8 May 2014: GW Pharmaceuticals plc (Nasdaq: GWPH,
AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform, announced that Justin Gover, GW's Chief Executive
Officer, is scheduled to present at the Bank of America Merrill
Lynch 2014 Health Care Conference in Las Vegas, NV on Tuesday, 13
May, 2014 at 4:20 p.m. PT (1:20 p.m. ET). The conference will be
held at the Encore at Wynn Las Vegas.
A live audio webcast of the presentation will be available
through GW's corporate website in the investor relations section
from the investor's calendar of events page at www.gwpharm.com. A
replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex, which is approved for the
treatment of spasticity due to multiple sclerosis in 25 countries.
Sativex is also in Phase 3 clinical development as a potential
treatment of pain in people with advanced cancer. This Phase 3
program is intended to support the submission of a New Drug
Application for Sativex in cancer pain with the U.S. Food and Drug
Administration and in other markets around the world. GW has a deep
pipeline of additional cannabinoid product candidates, including
Epidiolex which has received Orphan Drug Designation from the FDA
for the treatment of Dravet and Lennox-Gastaut syndromes, severe,
drug-resistant epilepsy syndromes. GW's product pipeline also
includes compounds in Phase 1 and 2 clinical development for
glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For
further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980
557000
Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500
(U.S.) 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen
(UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin 646 378 2900
Peel Hunt LLP (UK NOMAD) +44 20 7418 8900
James Steel / Clare Terlouw
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFLEEAITIIS
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Oct 2023 to Oct 2024